Expression of IFN-induced 2'-5'-oligoadenylate synthetases correlates with immune infiltration, revealing potential targets and new biomarkers for basal-like breast cancer prognosis.
Basal-like breast cancer prognosis
Immunotherapy
OAS family
Tumor-infiltrating immune cell
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
26
03
2020
revised:
15
08
2020
accepted:
16
08
2020
pubmed:
4
9
2020
medline:
26
5
2021
entrez:
4
9
2020
Statut:
ppublish
Résumé
Triple-negative breast cancer has been classified as basal-like immune activated (BLIA), basal-like immune-suppressed (BLIS), and two other subtypes, suggesting potential immune therapeutic targets for basal-like breast cancer (BLBC). 2'-5'-Oligoadenylate synthetases (OASs), identified from differentially expressed genes (DEGs) between BLIA and BLIS breast cancers (GSE76124), are involved in antiviral activity induced by interferons. However, the association between the four OASs and prognosis or tumor-infiltrating immune cells (TIICs) remains unclear. Expression, survival data, and immune correlations for OASs in BLBC were assessed using bioinformatics tools. We found that OASs were highly expressed in BLIA breast cancer. Survival analysis suggested that high transcriptional levels of OASs were associated with better overall survival, relapse-free survival, and distant metastasis-free survival in patients with BLBC. Moreover, the prognostic value of OASs with respect to different clinicopathological factors, and especially according to lymph node metastasis, in patients with BLBC was further assessed. Our findings elucidated the expression, prognostic role, and effect of OASs in TIICs on BLBC, which might promote the development of OAS-targeted immunotherapy for BLBC.
Identifiants
pubmed: 32882665
pii: S1567-5769(20)30922-X
doi: 10.1016/j.intimp.2020.106916
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Interferons
9008-11-1
2',5'-Oligoadenylate Synthetase
EC 2.7.7.84
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
106916Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.